Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):175–182. doi: 10.1097/QAI.0000000000001587

Figure 3.

Figure 3

Explant ex vivo HIV challenge over time by product. Control (no drug) biopsy is indicated as “BL” (baseline), for comparison, even though the biopsy may have followed the study product dosing by 12 weeks.